company background image
PVCT logo

Provectus Biopharmaceuticals OTCPK:PVCT Stock Report

Last Price

US$0.20

Market Cap

US$83.9m

7D

-0.3%

1Y

18.0%

Updated

26 Mar, 2024

Data

Company Financials

Provectus Biopharmaceuticals, Inc.

OTCPK:PVCT Stock Report

Market Cap: US$83.9m

PVCT Stock Overview

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes.

PVCT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Provectus Biopharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Provectus Biopharmaceuticals
Historical stock prices
Current Share PriceUS$0.20
52 Week HighUS$0.22
52 Week LowUS$0.056
Beta0.63
1 Month Change38.68%
3 Month Change97.20%
1 Year Change17.96%
3 Year Change181.03%
5 Year Change268.22%
Change since IPO-82.09%

Recent News & Updates

Recent updates

Shareholder Returns

PVCTUS PharmaceuticalsUS Market
7D-0.3%-0.2%0.6%
1Y18.0%23.9%29.5%

Return vs Industry: PVCT underperformed the US Pharmaceuticals industry which returned 23.1% over the past year.

Return vs Market: PVCT underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is PVCT's price volatile compared to industry and market?
PVCT volatility
PVCT Average Weekly Movement12.2%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PVCT's share price has been volatile over the past 3 months.

Volatility Over Time: PVCT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20024n/ahttps://www.provectusbio.com

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. The company’s lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis; and PV-305 for the treatment of infectious keratitis.

Provectus Biopharmaceuticals, Inc. Fundamentals Summary

How do Provectus Biopharmaceuticals's earnings and revenue compare to its market cap?
PVCT fundamental statistics
Market capUS$83.90m
Earnings (TTM)-US$3.17m
Revenue (TTM)US$601.44k

137.4x

P/S Ratio

-26.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PVCT income statement (TTM)
RevenueUS$601.44k
Cost of RevenueUS$1.61m
Gross Profit-US$1.00m
Other ExpensesUS$2.17m
Earnings-US$3.17m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0076
Gross Margin-166.91%
Net Profit Margin-527.24%
Debt/Equity Ratio-40.8%

How did PVCT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.